This site is intended for healthcare professionals only
LoginRegister

Alembic Pharma successfully completes USFDA inspection for Panelav facility

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli   |  
USFDA inspection
  • whatsapp
  • Telegram

Vadodara: Alembic Pharma has announced that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oral Solid Formulation Facility (F-I) located at Panelav.

This was a scheduled GMP inspection and was successfully completed without any Form 483 observation.

The inspection was conducted from 17th July, 2024 to 26th July, 2024.

Medical Dialogues team had earlier reported that the Company had received an Establishment Inspection Report (EIR) from the US FDA for the inspection carried out at the Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav.

Read also: Alembic Pharma gets USFDA EIR for Panelav Oncology formulation facility

Headquartered in Vadodara, Gujarat, Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. The company was founded in 1907. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.

Read also: Alembic Pharma gets USFDA nod for Fluphenazine Hydrochloride Tablets



alembic pharmaalembic pharma newsUSFDAUSFDA inspection
Ruchika Sharma
Ruchika Sharma

    Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    X